===========================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G/A
Amendment No. 2
Under the Securities Exchange Act of 1934
ARIAD PHARMACEUTICALS, INC.
----------------------------
(Name of Issuer)
COMMON STOCK, $.001 PAR VALUE
- ---------------------------------------------------------------------------
(Title of Class of Securities)
04033A 10 0
-----------------
(CUSIP Number)
December 15, 1999
-------------------------------------------------------
(Date of Event Which Requires Filing of This Statement)
Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:
[ ] Rule 13d-1(b)
[ x ] Rule 13d-1(c)
[ ] Rule 13d-1(d)
===========================================================================
Page 1 of 8
Exhibit Index is located at page 7
<PAGE> 2
CUSIP No. 04033A 10 0
___________________________________________________________________________
1) Name of Reporting Person and its Aventis Pharmaceuticals Inc.
I.R.S. Identification Number 44-0565557
___________________________________________________________________________
2) Check the Appropriate Box if (a)[ ]
a Member of a Group (b)[ x ]
___________________________________________________________________________
3) SEC Use Only
___________________________________________________________________________
4) Citizenship or Place of Organization Delaware
___________________________________________________________________________
5) Sole Voting Power 3,004,436
Number of ____________________________________________________
Shares
Beneficially 6) Shared Voting Power 0
Owned by ____________________________________________________________
Each
Reporting 7) Sole Dispositive Power 3,004,436
Person With ____________________________________________________________
8) Shared Dispositive Power 0
___________________________________________________________________________
9) Aggregate Amount Beneficially Owned 3,004,436
by Each Reporting Person
___________________________________________________________________________
10) Check Box If the Aggregate Amount [ ]
in Row (9) Excludes Certain Shares
___________________________________________________________________________
11) Percent of Class Represented 12.0%
by Amount in Row (9)
___________________________________________________________________________
12) Type of Reporting Person CO
___________________________________________________________________________
<PAGE> 3
CUSIP No. 04033A 10 0 13G
___________________________________________________________________________
1) Name of Reporting Person and its HMR Pharma, Inc.
I.R.S. Identification Number 43-1769328
___________________________________________________________________________
2) Check the Appropriate Box if (a)[ ]
a Member of a Group (b)[ x ]
___________________________________________________________________________
3) SEC Use Only
___________________________________________________________________________
4) Citizenship or Place of Organization Delaware
___________________________________________________________________________
5) Sole Voting Power 3,004,436
Number of ____________________________________________________
Shares
Beneficially 6) Shared Voting Power 0
Owned by ____________________________________________________________
Each
Reporting 7) Sole Dispositive Power 3,004,436
Person With ____________________________________________________________
8) Shared Dispositive Power 0
___________________________________________________________________________
9) Aggregate Amount Beneficially Owned 3,004,436
by Each Reporting Person
___________________________________________________________________________
10) Check Box If the Aggregate Amount [ ]
in Row (9) Excludes Certain Shares
___________________________________________________________________________
11) Percent of Class Represented 12.0%
by Amount in Row (9)
___________________________________________________________________________
12) Type of Reporting Person CO
___________________________________________________________________________
<PAGE> 4
CUSIP No. 04033A 10 0 13G
This Amendment No. 2 to the Statement on Schedule 13G of Aventis
Pharmaceuticals Inc., a Delaware corporation, and HMR Pharma, Inc., a Delaware
corporation, is filed solely to reflect the change of name of Hoechst Marion
Roussel, Inc., to Aventis Pharmaceuticals Inc. The following items of the
Statement on Schedule 13G are hereby amended to read as follows:
ITEM 2(a). NAME OF PERSON FILING:
- ---------- ----------------------
Aventis Pharmaceuticals Inc.
HMR Pharma, Inc.
ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
- ---------- ------------------------------------------------------------
Aventis Pharmaceuticals Inc.
10236 Marion Park Drive
Kansas City, Missouri 64137-1405
HMR Pharma, Inc.
10236 Marion Park Drive
Kansas City, Missouri 64137-1405
ITEM 2(c). CITIZENSHIP:
- ---------- ------------
Delaware As To Both Aventis Pharmaceuticals Inc. And
HMR Pharma, Inc.
ITEM 4. OWNERSHIP
- ------- ---------
(a): AMOUNT BENEFICIALLY OWNED:
As Of 11/08/99 3,004,436 Shares Of Series B Convertible
Preferred Stock. The Shares Are Convertible Into Common
Stock On A Share-For-Share Basis.
(b): PERCENT OF CLASS:
12.0%
(c): NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS:
(i) Sole power to vote or to direct the vote: 3,004,436
(ii) Shared power to vote or to direct the vote: 0
(iii) Sole power to dispose or to direct the disposition of: 3,004,436
(iv) Shared power to dispose or to direct the 0
disposition of:
<PAGE> 5
CUSIP No. 04033A 10 0 13G
SIGNATURE
----------
After reasonable inquiry and to the best of my knowledge and belief,
I certify that the information set forth in this statement is true, complete
and correct.
December 22, 1999
---------------------------------
(Date)
HMR PHARMA, INC.
/s/ Rebecca R. Tilden
---------------------------------
(Signature)
Rebecca R. Tilden
Vice President and Assistant Secretary
---------------------------------
(Name/Title)
<PAGE> 6
CUSIP No. 04033A 10 0 13G
SIGNATURE
----------
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete
and correct.
December 22, 1999
---------------------------------
(Date)
Aventis Pharmaceuticals INC.
/s/ Rebecca R. Tilden
---------------------------------
(Signature)
Rebecca R. Tilden
Vice President and Secretary
---------------------------------
(Name/Title)
<PAGE> 7
CUSIP No. 04033A 10 0 13G
EXHIBIT INDEX
Exhibit No. Description Page No.
- ----------- ------------ ---------
99.A Agreement to File Jointly dated December 8
22, 1999, by and between Aventis
Pharmaceuticals Inc. and HMR Pharma, Inc.
<PAGE> 8
CUSIP No. 04033A 10 0 13G
EXHIBIT 99.A
AGREEMENT TO FILE JOINTLY
We, the undersigned, hereby express our agreement that the attached
Schedule 13G is filed on behalf of each of us.
AVENTIS PHARMACEUTICALS INC.
Date: December 22, 1999 By: /s/ Rebecca R. Tilden
--------------------------
Rebecca R. Tilden
Vice President and Secretary
HMR PHARMA, INC.
Date: December 22, 1999 By: /s/ Rebecca R. Tilden
--------------------------
Rebecca R. Tilden
Vice President and Assistant Secretary
